Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice

Purpose: In this study the relationship between therapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and of the expression of proliferation markers (ki67 and S-phase fraction) and tumour suppressor gene p53 was analyzed using a human ovarian cancer xenograft model.

Methods: Biopsy material from one human ovarian cancer was expanded and transplanted into 102 nude mice. The mice were divided into six groups with different intraperitoneal treatments with paclitaxel, cisplatin, vinorelbine, titanocene dichloride and a control group treated with 0.9% saline solution. After the observation period the tumours were extracted and immunohistochemically stained with monoclonal antibodies against ki67 and p53. The S-phase-fraction was identified by flow cytometry.

Results: There where no statistically significant differences. Regarding the treatment groups, the vinorelbine-group showed the highest percentage (53.3%) and the titanocene dichloride-3x40 mg/kg-group the lowest percentage (7.1%) of ki67-positive specimens, whereas in the control group 35.7% of the specimens were positively stained for ki67. The results for the expression of p53 were similar. The vinorelbine-group had the highest percentage of p53-positive specimens (60%), in both titanocene-groups no specimen showed a positive staining for p53 and in the control group 7.1% of the specimens were positively stained for p53. The mean S-phase-fraction was 14.48% (SD +/- 3.98), no statistically significant relation between S-phase-fraction and expression of p53 (p = 0.883) or of ki67 (p = 0.351) could be shown. The change of tumour volume was independent of the results for ki67, p53 and the S-phase-fraction.

Conclusion: Although, as previously published, a significant difference of tumour volume change occurred between the treatment groups, in this study we could not find a relation between this change of tumour volume and the expression of p53 or ki67. The absolute number of p53- and ki67-positive staining specimens was too small for statistical analysis, therefore the relevance of the differences between the different treatment groups and the control remains unclear. The results for the S-phase-fraction showed no correlation between the change of tumour volume, different treatment protocols or the expression of p53- and ki67. Our findings contribute to the controversy of the influence of chemotherapy on the expression of proliferation markers and p53.

Nude mice; Ovarian cancer; Chemotherapy; Proliferation markers; p53

[1] World Health Organisation, International Agency for Research on Cancer European Commission: "Survival of cancer patients in Europe, the EUROCARE study". In: Berrino F., Sant M., Verdecchia A., Capocaccia R., Hakulinen T., Esteve J. (eds.) IARC Publication, 1995, No. 132, Lyon.

[2] du Bois A., Richter B., Warm M. et al.: "Cisplatin/paclitaxel versus carboplatin/paclitaxel as !st-line treatment in ovarian cancer" (abstract). Proc. Am. Soc. Clin. Oneal., 1998, 17, 361a.

[3] du Bois A., Ltick H.J., Meier W. et al.: "Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an AGO Study Group trial" (abstract). Proc. Am. Soc. Clin. Oncol., 1999, /8, 356a.

[4] Sevelda P.: "Second-line therapy of ovarian carcinoma". Onkolog gie， 2000, 23, 593.

[5] du Bois A., Ltick H.J., Bauknecht T.: "2nd-line Chemotherapienach Platin- oder Platin-Paclitaxel-haltiger Primartherapie beim Ovarialkarzinom: eine sytematische Ubersicht der publizierten Daten bis 1998". Geburtsh Frauenheilk, 2000, 60, 41.

[6] Povlson C.O. : "Heterotransplants of human tumors in nude mice". Antibiot. Chemother., 1980, 28, 15.

[7] Kleine W.: "Clinical prediction of experimental chemotherapy of gynaecological tumor xenografts". Behring Inst. Mitt., 1984, 74, 337.

[8] Elkas J.C., Baldwin R.L., Pegram M., Tseng Y., Slamon D., Karlan B.Y.: "A human ovarian carcinoma murine xenograft model useful for preclinical trials". Gynecol. Oncol., 2002, 2, 200.

[9] Moebius VJ., Stein R., Kieback D.G., Runnebaum I.B., Sass G., Kreienberg R.: "Antitumour activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivates". Anticancer Res., 1997, 17, 815.

[10] Kopf-Maier P.:'Tumour inhibition by titanocene complexes influence on xenografted human adenocarcinomas of the gastrointestinal tract". Cancer Chemother. Pharmacol., 1989, 23, 225.

[11] Kurbacher C.M., Nagel W., Mallmann P. et al.: "In vitro activity of titanocenedichloride in human renal cell carcinoma compared to conventional antineoplastic agents". Anticancer Res., 1994, 14, 1529.

[12] Harstrick A., Schmoll H.J., Sass G., Poliwoda H., Rustum Y 'Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines". Eur. J. Cancer, 1993, 29, 1000.

[13] Kopf-Maier P.: "Complexes of metals other than platinum as antitumour agents". Eur. J. Clin. Pharmacol., 1994, 47, 1.

[14] Kurbacher C.M., Bruckner H.W., Andreotti P.E., Kurbacher J.A., Sass G., Krebs D.: "In vitro activity of titanocenedichloride versus cisplatin in four ovarian cell lines evaluated by microtiter plate bioluminescence assay". Anticancer Drugs, 1995, 6, 697.

[15] Cao S., Durrani F.A., Baumgai·t J., Sass G., Rustum Y.: "Titanocene dichloride a new organometallic compound, active in vivo against varieties of human tumours with differential sensitivity to doxoru bicin and cisplatin". Proceedings of the 86'" Annual Meeting of the American Association for Cancer Research, 1995, 36, 391.

[16] Melendez E.: "Titanium complexes in cancer treatment". Crit. Rev. Oneal. Hematol., 2002, 42, 309.

[17] Mross K., Robben-Bathe P., Edler L., Baumgart J., Berdel W.E., Fiebig H., Unger C.: "Phase I clinical trial of a day-I, -3, -5 every 3 weeks schedule with titanocene dichloride (MKT 5) in patients with advanced cancer". Onkologie, 2000, 23, 576.

[18] Christodoulou C.V., Ferry D.R., Fyfe D.W., Young A., Doran J., Sheehan T.M. et al.: "Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer". J. Clin. Oncol., 1998, 16, 2761.

[19] Christodoulou C.V., Eliopoulos A.G., Young L.S., Hodgkins L., Ferry D.R., Kerr DJ.: "Anti-proliferative activity and mechanism of action in titanocene dichloride". Br. J. Cancer, 1998, 77, 2088.

[20] Kopf-Maier P.: "Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma". Anticancer Res., 1999, 19,493.

[21] Lummen G., Sperling H., Luboldt H., Otto T., Rubbcn H.: "Phase II trial of titanocene dichloride in advanced renal-cell carcinoma". Cancer Chemother. Pharmacol., 1998, 42, 415.

[22] Hollstein M., Sidransky D., Vogelstein B., Harris C.C.: "p53 mutations in human cancers". Science, 1991, 253, 49.

[23] Amundson S.A., Myers T.G., Fornace A.J.: "Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress". Oncogene, 1998, 17, 3287.

[24] Shelling A.N., Cooke I.E., Ganesan T.S.:'The genetic analysis of ovarian cancer". Br. J. Cancer, 1995, 72, 521.

[25] Rohlke P., Milde-Langosch K., Weyland C., Pichlmayer U., Jonat W., Loning T.: "p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with ki67 immunoreactivity". J. Cancer Res. Clin. Oneal., 1997, 123, 496.

[26] Skirnisdottir I., Sorbe B., Karlsson M., Seidal T.: "Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma". Int. J. Oneal., 2001, 19, 1295.

[27] Spacek J., Jilek P., Petera J., Tesarik Z.: "Histopathologic factors, serum markers and selected molecular biologic factors in ovarian carcinoma". Ceska Gynekol., 2002, 67, 343.

[28] Frutuoso C., Silva M.R., Amaral N., Martins I., De Oliveira C., De Oliveira H.M.: "Prognosis value of p53, C-erB-2 and ki67 in ovarian carcinoma". Acta Med. Port.,2 001, 14, 277.

[29] Tachibana M., Watanabe J., Matsushima Y., Nishida K., Kobayashi Y., Fujimura M., Shiromizu K.: "Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma and related proteins". Int. J. Gynecol. Cancer, 2003, 13, 598.

[30] Ikeda K., Sakai K., Yamamoto R., Hareyama H., T sumura N., Watari H. et al.: "Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1 and p53 in stages II-IV in ovarian cancer". Int. J. Gynecol. Cancer, 2003, 13, 776.

[31] Berker B., Dunder I., Ensari A., Cengiz S.D., Simsek E.: "Prognostic significance of apoptotic index and bcl-2 and p53 expression in epithelial ovarian carcinoma". Eur. J. Gynecol. Oneal., 2002, 23, 505.

[32] Tomic S., Ilic Forko J., Babic D., Sundov D., Kuret S., Andel!novic S.: "c-erbB-2, p53 and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma". Croat. Med. J., 2003, 44, 429.

[33] Havrilesky L., Darcy M., Hamdan H., Priore R.L., Leon J., Bell J., Berchuck A., Gynecologic Oncology Group Study: "Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study" J. Clin. Oncol., 2003, 21, 3814.

[34] Berker B., Dunder I., Ensari A., Cengiz S.D.: "Prognostic value of p53 accumulation in epithelial ovarian carcinomas". Arch. Gynecol. Obstet., 2002, 266, 205.

[35] Nakayama K., Takebayashi Y., Nakayama S., Hata K., Fujiwak1 R., Fukumoto M., Miyazaki K.: "Prognostic value of overexpression of p53 in human ovarian cancer patients receiving cisplatin" Cancer Lett., 2003, 192, 227.

[36] Gaducci A., Cosio S., Muraca S., Genazzani A.R.: "Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: Biological data and clinical implications". Eur. J. Gynecol. Oncol., 2002, 23, 390.

[37] Goff B.A., Ries J.A., Els L.P., Coltrera M.D., Gown A.M. "Immunophenotype of ovarian cancer as a predictor of clinical outcome: evaluation at primary surgery and second-look procedure". Gynecol. Oncol., 1998, 70, 378.

[38] Henriksen R., Strang P., Backstrom T., Wilander E., Tribukait B., Oberg K.: "Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers". Anticancer Res., 1994, 14, 603.

[39] Htittner P.C., Weinberg D.S., Lage J.M.: "Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry" Am. J. Pathol., 1992, 141, 699.

[40] Thompson A.M., Anderson T.J., Condie A., Prosser J., Chetty U., Carter D.C. et al.: "p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters". Int. J. Cancer, 1992, 50, 528.

[41] Mink D.: "Zusammenhange zwischen der Expression von Steroidhormonrezeptoren und der proliferativen Aktivitat beim Mammakarzinom". Habilitationsschrift,Medizinische Fakultat der Universitatdes Saarlandes, 1995, Homburg/Saar.

[42] Garzetti G.G., Ciavattini A., Goteri G., de Nictolis M., Stramazott1 D., Lucarini G., Biagini G.: "Ki67 antigen immunostaining (MIB I Monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance". Gynecol. Oncol., 1995, 56, 169.

[43] Kolfschoten G.M., Hulscher T.M., Pinedo H.M., Boven E.: "Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts" Br. J. Cancer, 2000, 83, 921.

[44] Kimmig R., Wimberger P.，Hillemanns P., Kapsner T., Caspari C., Hepp H.: "Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labelled tumor cells". Gynecol. Oncol., 2002, 84, 21.

[45] Vindelov L.L., Christensen l.J., Nissen N.I.: "A detergent-trypsm method for the preparation of nuclei for flow cytometric DNA analysis". Cytomet八',1983,3, 323.

[46] Azar H.A., Fernandez S.B., Bros L.M., Sullivan J.L.: "Human tumour xenografts in athymic nude mice: chemotherapy trials in serially transplanted tumours". Ann. Clin. Lab. Sci., 1982, 12, 51.

[47] Kyriazis A.A., Kyriazis A.P., Kereiakes J.G., Soloway M.S., McCombs W.B.: "Histopathologic evaluation of response to treatment of human tumours grown in the nude mice". Exp. Cell. Biol., 1983, 51, 83.

[48] Shorthouse A.J., Smyth J.F., Steel G.G., Ellison M., Mills J., Peckham M.J.: "The human tumour xenograft a valid model in experimental chemotherapy". Brit. J. Surg., 1980, 67, 715.

[49] Steel G.G., Courtenay V.D., Peckham M.J.: "The response to chemotherapy of a variety of human tumour xenografts". Cancer, 1983, 47, I.

[50] Friedrich M., Villena-Heinsen C., Farnhammer C., Schmidt W "Effects of vinorelbine and titanocene dichloride on human tumour xenografts in nude mice". Eur. J. Gynaecol. Oneal., 1998, 19, 333.

[511 V仆lena-Heinsen C., Friedrich M., Ertan A.K., Schmidt W "Human tumour xenografts in nude mice: chemotherapy trials with titanocene dichloride in different dosages". Clin. Exp. Obstet. Gynecol., 1998, 25, 5.

[52] Yillena-Heinsen C., Friedrich M., Ertan A.K., Farnhammer C., Schmidt W.: "Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride". Anticancer Drugs, 1998, 9, 557.